Niraparib in the Treatment of Previously Treated Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Abstract

Homologous recombination deficiency is a critical biologic feature of ovarian cancer. This weakness in DNA damage repair relies on functional poly(ADP-ribose) polymerase. Niraparib is a poly(ADP-ribose) polymerase inhibitor, orally available and initially approved for maintenance therapy in women with ovarian cancer by the US FDA in 2017 and by the EMA in 2017 for the same indication. Ovarian cancer represents the most lethal of gynecologic malignancies. The efficacy of niraparib has changed the landscape of ovarian cancer treatment, but overall survival data is still to come. This review summarizes the data regarding niraparib mechanism of action, toxicities, single agent efficacy and novel combinations in ovarian cancer.

Keywords::

• homologous recombination deficiency
• niraparib
• ovarian cancer
• PARP inhibitors

Financial & competing interests disclosure

BJ Rimel: Tesaro/GSK (advisory board participant), AstraZeneca (advisory board participant), Clovis (Advisory board participant). Dr Randall reports honoraria from BluPrint Oncology, Physician’s Education Resource, Curi Science and Products in Knowledge. Consulting fees from Astra Zeneca, Clovis, Novocure, GOG Foundation, Merck, Mersana, and Agenus. She is on a speaker bureau for AstraZeneca, Tesaro and Merck. K Moore reports advisory board participation for AbbVie, Aravive, AstraZeneca, Eisai, Immunogen, GSK/Tesaro, Genentech/Roche, Merck, Mersana, VBL Therapeutics, Vavotar, Tarveda and Myriad. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Company review disclosure

In addition to the peer-review process, with the author’s consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the author at their discretion and based on scientific or editorial merit only. The author maintained full control over the manuscript, including content, wording and conclusions.

Additional information

Funding

BJ Rimel: Tesaro/GSK (advisory board participant), AstraZeneca (advisory board participant), Clovis (Advisory board participant). Dr Randall reports honoraria from BluPrint Oncology, Physician’s Education Resource, Curi Science and Products in Knowledge. Consulting fees from Astra Zeneca, Clovis, Novocure, GOG Foundation, Merck, Mersana, and Agenus. She is on a speaker bureau for AstraZeneca, Tesaro and Merck. K Moore reports advisory board participation for AbbVie, Aravive, AstraZeneca, Eisai, Immunogen, GSK/Tesaro, Genentech/Roche, Merck, Mersana, VBL Therapeutics, Vavotar, Tarveda and Myriad. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.